Cycle race boosts funds for Belfast charity | Diaceutics

Cycle race boosts funds for Belfast charity

August 31st, 2017

Philip White and Sarah Colgan of Diaceutics present the donation from Philip’s cycle ride to the Belfast City Hospital Cancer Centre, Northern Ireland.

Huge congratulations to Philip White, Chief Financial Officer of Diaceutics, who took part in the Prudential Ride London-Surrey 100 event in July 2017. On a beautiful day, Philip took to the streets and hills with his teammates and thousands of other cyclists, following the course set for the 2012 London Olympics. Amazingly, this was his first ever cycle race after only taking up the sport in April. Not only did he complete the 100-mile race in an impressive 6 hours 20 minutes, he also raised £9,400 for Friends of the Cancer Centre, a charity supporting the Belfast City Hospital Cancer Centre and local people affected by the disease. Proving his CFO credentials, this was nearly double his original target of £5,000.

Cancer treatment, and getting the right diagnostic test to patients at the right time, is a major part of our work at Diaceutics and, as Philip says, it was rewarding to focus on this in a different way. The smile says it all, so perhaps he’ll be back next year. Well done, Philip, from everyone at Diaceutics.

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications